Contact this trialFirst, we need to learn more about you.
Histone Deacetylase (HDAC) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
Recruiting3 awardsPhase 4
Toronto, Ontario
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service